Replimune Group (REPL)
(Delayed Data from NSDQ)
$9.86 USD
+0.13 (1.34%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $9.85 -0.01 (-0.10%) 7:46 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 29% (72 out of 250)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.35 | 9.99 |
Current Quarter Estimate | -0.79 | 7.43 | 61.00 |
Year Ago Quarter Estimate | -0.90 | 0.12 | 54.84 |
Next Quarter Estimate | -0.79 | 7.81 | 63.00 |
Next Year Estimate | -2.52 | 37.76 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 2.78 | 17.50 | 15.67 |
Next Year | 20.00 | 9.40 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | NA | 21.40 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -2.18 |
Price/Book (MRQ) | 1.56 | 1.91 |
Price/Cash Flow (MRFY) | NA | 15.24 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -87.29% |
Return on Equity (TTM) | -52.15% | -47.30% |
Debt to Equity (MRQ) | 0.16 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.